Cellular Origins and Fresenius Kabi, an operating company of Fresenius, have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs) with the goal of digitally and physically integrating Fresenius Kabi’s suite of cell therapy processing technologies within Cellular Origins’ CGT robotic manufacturing platform Constellation. This work aims to assist cell therapy developers in manufacturing their therapies at scale using their preferred processing to...